TRPV4 and colitis: Studies have shown that the activation of TRPV4 by intracolonic administration of agonists in mice acutely induces pro-inflammatory cytokine releases and colon inflammation [23], whereas pharmacological TRPV4 antagonism abolishes the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colon inflammation [24].